GlassScriptPhysician profile
Jose Ruiz
NPI 1861842601
$3,181.23
in general payments reported to CMS, 2019-2025
24 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,156 · 2023: $255 · 2024: $742 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.66 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,303.62 | 2022-2023 | Exalt Model D |
| Janssen Biotech, INC. | $285.02 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $233.49 | 2023-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $202.92 | 2023-2025 | |
| Madrigal Pharmaceuticals | $167.31 | 2024-2025 | Rezdiffra |
| Qol Medical, LLC | $113.34 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $104.86 | 2024-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $94.65 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $79.72 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $77.50 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $70.06 | 2025 | Zenpep |
| Davol INC. | $68.80 | 2025 | Phasix Mesh |
| Phathom Pharmaceuticals, INC. | $58.39 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.83 | 2024 | Xifaxan |
| Exact Sciences Corporation | $51.03 | 2023-2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $48.23 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $27.50 | 2025 | Iqirvo |
| Conmed Corporation | $24.63 | 2025 | Conmed Hemostasis, Conmed Biliary |
| Pharmacosmos Therapeutics INC. | $24.24 | 2024 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $23.95 | 2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $21.15 | 2024 | Terlivaz |
| Vivus LLC | $18.97 | 2025 | Pancreaze |
| Evoke Pharma, INC. | $15.61 | 2024 | |
| Novo Nordisk INC | $14.41 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.